Trial Profile
HT-100 Long-term Safety and Pharmacodynamics in Patients With DMD Who Have Completed Protocols HALO-DMD-01 and HALO-DMD-02
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2019
Price :
$35
*
At a glance
- Drugs Halofuginone (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Akashi Therapeutics
- 05 Jul 2017 Status changed from recruiting to discontinued.
- 20 Aug 2015 New trial record